Funding for this research was provided by:
Foundation for the National Institutes of Health (HL123920, HL137093, HL144002, HL146153, HL147357, and HL149940)
American Heart Association (18TPA34230092 and 19EIA34660286)
Received: 23 June 2020
Accepted: 30 April 2021
First Online: 17 June 2021
: K.C. is a co-founder and equity holder of BreStem Therapeutics Inc. P.-U.C.D. reports compensation for consulting from BreStem Therapeutics Inc. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.